Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
(NASDAQ: NTLA) Delayed: 15.75 +0.08 (0.51%)
Previous Close $15.67    52 Week High $30.40 
Open $15.87    52 Week Low $11.86 
Day High $16.32    P/E N/A 
Day Low $15.57    EPS $0.00 
Volume 5,103,380